Perry J. Sternberg.

DEL MAR, Calif.—Sydnexis, Inc., a pre-commercial stage biopharmaceutical company focused on the treatment of pediatric myopia progression, has announced the appointment of Perry J. Sternberg as chief executive officer and as a member of the board of directors, effective August 5, 2024. According to the announcement, Sternberg is an accomplished pharma/biotech executive with more than 30 years experience in the industry and 15 years in eyecare. He will help guide Sydnexis’ strategic direction and next phase of growth, the company stated.

“Perry’s appointment comes at a pivotal time for Sydnexis as we continue to advance our lead asset, SYD-101, to slow the progression of pediatric myopia and the risk of associated comorbidities,” said Jeffry Weinhuff, managing partner at Visionary Venture Fund and lead board director at Sydnexis. “Perry has deep expertise in commercialization of new therapies across diverse markets and extensive experience leading organizational growth and transformation. He will be a tremendous asset to Sydnexis.”

Sternberg’s tenure in eyecare spans 15 years across Novartis, Bausch + Lomb, and Shire, the announcement stated, where he was responsible for the U.S. commercial organization and managing the company’s product portfolio in five franchises. Sternberg led the build-out of the ophthalmic business unit and launch in 2016 of Xiidra, an FDA-approved treatment for the signs and symptoms of dry eye disease.

 
“The Sydnexis team has an industry-leading track record in eyecare. I am excited to join and work with Patrick Johnson, president, and the rest of the management team,” said Sternberg. “Progression of pediatric myopia is a serious condition with significant, growing unmet need and no FDA-approved pharmacological treatment options. I look forward to collaborating with this talented team to bring such an innovative treatment option like SYD-101 to pediatric patients, their families and clinicians.”